



NBMI Invited to Present at International Conference on Biological Applications of Magnetic Carriers

Edmond, OK – (April 14, 2006): Charles Seeney, Founder and CEO of NanoBioMagnetics announced today from the BIO 2006 Conference in Chicago that the vetting committee of the 6th Annual International Conference on Scientific and Clinical Applications of Magnetic Carriers has selected two NBMI papers for publication at the conference. The first, a speaker presentation, titled "Magnetic Vectoring of Magnetically Responsive Nanoparticles Within The Murine Peritoneum," will be presented by Dr. Jim Klostergaard, Professor of Molecular and Cellular Oncology at The M D Anderson Cancer Center (MDACC), and Principal Investigator on NBMI's collaboration with MDACC studying the site-specific vectoring of chemotherapeutics.

According to Dr Klostergaard, "This is an important opportunity to present our magnetic targeting approach for drug delivery to our peers in the academic and industrial communities," says Klostergaard. "To date, we have focused our initial efforts on developing and validating essential aspects of magnetic nanoparticle localization *in vivo* and in tumor-bearing animal models. We are now poised to move to the next phase wherein we will evaluate the anti-tumor effects of our proprietary nanoparticle-prodrug formulations, and compare their effectiveness to that of standard chemotherapeutics." Dr. Klostergaard will present data demonstrating, in a scientific first, magnetic vectoring of NBMI's nanoparticles in a live mouse model.

Also accepted for publication at the conference will be a technical poster by Dr. William Yuill, NBMI Principal Investigator on nanomaterials development, titled "Modeling Mass Transfer Process for Targeting Drugs with Magnetically Responsive Nanoparticles." Dr. Yuill's paper establishes the scientific basis for magnetic vectoring theory.

This is the third international conference in 2006 at which NBMI has been selected to present. The company also has been invited to speak at the joint Nanotech 2006 and TechConnect Summit in Boston, MA, and the TCI International Technology Transfer Forum in Washington, DC, in May. These presentations will be made by Charles Seeney, NBMI Founder and CEO.

"We have made significant advancements in vectored drug delivery over the past few months," says Charles Seeney, President and CEO of NBMI. "And, being accepted to present at these prestigious international conferences is certainly a reflection of the interest we are attracting in the international scientific and business communities." Seeney notes that attendees to this conference will be among the "who's who" of research in this field affording NBMI the opportunity to investigate new collaborations.

"The significance of these nanotechnology conferences comes into sharp focus when you consider the growth of nanotechnology initiatives among global corporations," says Seeney. "According to Lux Research, 148 global corporations have nanotechnology initiatives today. Lux is predicting this number to grow to 290 by 2008."

Contact Info:

Charles Seeney

Dennis Donaldson

V: 405.844.5118

F: 405.844.4115

info@nanobmi.com

124 N. Bryant Ave., Suite C-3

Edmond, OK 73034

Safe Harbor Statement

Certain statement included in this press release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to, among other things, plans and timing for the introduction or enhancement of products and services, statements about future market conditions, supply and demand conditions, and other expectations, intentions and plans contained in this press release that are not historical fact and involve risks and uncertainties. The company's expectations regarding future revenues are dependent upon the ability to develop and supply products and services that meet defined specifications. When used in this press release, the words "plan," "expect," "believe," and similar expressions are generally considered forward-looking statements. These statements reflect current expectations.